LB-100 plus Doxorrubicin

Phase 2Small molecule

GGrupo Espanol de Investigacion en Sarcomas

LB-100 plus Doxorrubicin is one of 55 small molecule programs targeting Soft Tissue Sarcoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Soft Tissue SarcomaActive, not recruiting

Soft Tissue SarcomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

60 competitors in Soft Tissue Sarcoma

#DrugCompanyPhaseTrials

Votrient

Novartis

Approved

14 2

Adriamycin

Pfizer

Phase 3

36 3

Adriamycin

Pfizer

Phase 3

27 4

Lynparza

AstraZeneca

Approved

1 5

Idamycin

Pfizer

Approved

—6

Ifex

BBaxter Healthcare Corporation

Phase 3

32 7

Yondelis

AApotex Inc.

Phase 3

16 8

Farydak

SSecuraBio

Approved

—9

Treanda

AAzurity Pharmaceuticals

Neulasta

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas

Active, not recruiting·GGrupo Espanol de Investigacion en Sarcomas·Phase 1/2·NCT05809830·152 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LB-100 plus Doxorrubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LB-100 plus Doxorrubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LB-100 plus Doxorrubicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Grupo Espanol de Investigacion en Sarcomas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGrupo Espanol de Investigacion en Sarcomas

LB-100 plus Doxorrubicin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

References

Drug Info

Quick Facts

Related News